Multiply-resistant gram-negative bacteria: Where do we go from there?;Les bacilles à Gram négatif multi-résistants: où va-t-on ?

Journal des Anti-Infectieux

Volumn 13, Issue 2, 2011, Pages 122-132

  Lucet, J C ^a   Birgand, G ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Bacterial; Beta lactamases metabolism; Cross infection; Drug resistance; Enterobacteriaceae infections drug therapy prevention control; Gram negative bacterial infections ; Infection control ; methods; Multiple; Patient isolation; Practice guidelines standards; prevention control

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEMASE; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; NONHUMAN; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 79957957250     PISSN: 22106545     EISSN: 22106545     Source Type: Journal    
DOI: 10.1016/j.antinf.2011.03.006     Document Type: Article

References (60)

1. Bratu S., Landman D., Haag R., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York city: a new threat to our antibiotic armamentarium. Arch Intern Med 2005, 165(12):1430-1435.
2. Sinaii N. Charting the course for the future of science in healthcare epidemiology: results of a survey of the membership of the Society of healthcare epidemiology of America. Infect Control Hosp Epidemiol 2010, 31(7):669-675.
3. Harris A.D., McGregor J.C., Furuno J.P. What infection control interventions should be undertaken to control multidrug-resistant Gram-negative bacteria?. Clin Infect Dis 2006, 43(Suppl 2):S57-S61.
4. Bilavsky E., Schwaber M.J., Carmeli Y. How to stem the tide of carbapenemase-producing enterobacteriaceae? Proactive versus reactive strategies. Curr Opin Infect Dis 2010, 23(4):327-331.
5. Maragakis L.L. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit Care Med 2010, 38(8 Suppl):S345-S351.
6. Haut Conseil de la santé publique. Recommandations relatives aux mesures à mettre en œuvre pour prévenir l'émergence des entérobactéries BLSE et lutter contre leur dissémination. Available at: accessed.
7. Haut Conseil de la santé publique. Dépistage du portage digestif des bactéries commensales multirésistantes aux antibiotiques importées en France à l'occasion du rapatriement de patients en provenance de l'étranger et maîtrise de leur diffusion. Available at: accessed.
8. Valverde A., Coque T.M., Sanchez-Moreno M.P., Rollan A., Baquero F., Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004, 42(10):4769-4775.
9. Lo W.U., Ho P.L., Chow K.H., Lai E.L., Yeung F., Chiu S.S. Fecal carriage of CTXM type extended-spectrum beta-lactamase-producing organisms by children and their household contacts. J Infect 2010, 60(4):286-292.
10. Leflon-Guibout V., Blanco J., Amaqdouf K., Mora A., Guize L., Nicolas-Chanoine M.H. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia Coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008, 46(12):3900-3905.
11. European antimicrobial resistance surveillance system (EARSS). Annual report 2009. Available at: Accessed 2011. http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx.
12. Réseau d'alerte d'investigation et de surveillance des infections nosocomiales (Raisin). Surveillance des bactéries multirésistantes dans les établissements de santé en France Réseau BMR-Raisin-Résultats 2009. Available at: Accessed 2011. http://www.invs.sante.fr/publications/2011/surveillance_bacteries_multiresistantes/rapport_raisin_resultats_2009.pdf.
13. Nordmann P., Cuzon G., Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9(4):228-236.
14. Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece - a review of the current evidence. Euro Surveill 2008, 13(4).
15. Kumarasamy K.K., Toleman M.A., Walsh T.R., et al. Emergence of a new antibiotic resistance mechanism in India. Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10(9):597-602.
16. Leavitt A., Carmeli Y., Chmelnitsky I., Goren M.G., Ofek I., Navon-Venezia S. Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. Antimicrob Agents Chemother 2010, 54(7):3002-3006.
17. Institut de veille sanitaire. Entérobactéries productrices de carbapénèmases. Available at: accessed.
18. Kassis-Chikhani N., Decre D., Gautier V., et al. First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French university hospital. J Antimicrob Chemother 2006, 57(1):142-145. [Epub 2005].
19. Decre D., Birgand G., Geneste D., et al. Possible importation and subsequent cross-transmission of OXA-48-producing Klebsiella pneumoniae France. Euro Surveill 2010, 15(46).
20. Tangden T., Cars O., Melhus A., Lowdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010, 54(9):3564-3568.
21. Villegas M.V., Hartstein A.I. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003, 24(4):284-295.
22. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21(3):538-582.
23. Réseau d'alerte diedsdinR. Enquête nationale de prévalence des infections nosocomiales, France, juin 2006. Available at: accessed.
24. CCLIN Sud Ouest. Surveillance des bactéries multiréistantes à partir du laboratoire de microbiologie Available at: accessed.
25. Souli M., Galani I., Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008, 13(47).
26. Scott P., Deye G., Srinivasan A., et al. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis 2007, 44(12):1577-1584.
27. Trautmann M., Lepper P.M., Haller M. Ecology of Pseudomonas aeruginosa in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. Am J Infect Control 2005, 33(5 Suppl 1):S41-S49.
28. Naas T., Coignard B., Carbonne A., et al. VEB-1 Extended-spectrum beta-lactamase-producing Acinetobacter baumannii, France. Emerg Infect Dis 2006, 12(8):1214-1222.
29. Cuttelod M., Senn L., Terletskiy V., et al. Molecular epidemiology of Pseudomonas aeruginosa in intensive care units over a 10-year period (1998-2007). Clin Microbiol Infect 2011, 17(1):57-62.
30. Donskey C.J., Chowdry T.K., Hecker M.T., et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patient. N Engl J Med 2000, 343(26):1925-1932.
31. Ben-Ami R., Rodriguez-Bano J., Arslan H., et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009, 49(5):682-690.
32. Rodriguez-Bano J., Picon E., Gijon P., et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010, 50(1):40-48.
33. Walsh T.R., Weeks J., Livermore D.M., Toleman M.A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011, 11:355-362.
34. Schnell D., Kouatchet A.T., Lecuyer H., et al. Is extended-spectrum beta-lactamase-producing Escherichia coli rectal carriage at hospital admission predictable? Risk factors at hospital admission. J Hosp Infect 2010, 76(2):178-180.
35. Zahar J.R., Lanternier F., Mechai F., Filley F., Taib F., Mainot E.L., et al. Duration of colonisation by Enterobacteriaceae producing extended-spectrum beta-lactamase and risk factors for persistent faecal carriage. J Hosp Infect 2011, 75:76-78.
36. Apisarnthanarak A., Bailey T.C., Fraser V.J. Duration of stool colonization in patients infected with extended spectrum beta lactamase producing E. coli and K. pneumoniae. J Hosp Infect 2008, 46:1322-1323.
37. Valverde A., Grill F., Coque T.M., et al. High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 2008, 46(8):2796-2799.
38. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 60(5):913-920.
39. De Kraker M.E., Wolkewitz M., Davey P.G., et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2010.
40. Sidjabat H.E., Silveira F.P., Potoski B.A., et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis 2009, 49(11):1736-1738.
41. Barbier F., Ruppe E., Giakkoupi P., et al. Genesis of a KPC-producing Klebsiella pneumoniae after in vivo transfer from an imported Greek strain. Euro Surveill 2010, 15(1).
42. Harris A.D., Perencevich E.N., Johnson J.K., et al. Patient-to-patient transmission is important in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae acquisition. Clin Infect Dis 2007, 45(10):1347-1350.
43. Harris A.D., Kotetishvili M., Shurland S., et al. How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition. Am J Infect Control 2007, 35(2):97-101.
44. Donskey C.J. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis 2006, 2(43 Suppl):S62-S69.
45. Kaier K., Frank U., Hagist C., Conrad A., Meyer E. The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis. J Antimicrob Chemother 2009, 63(3):609-614.
46. Pena C., Pujol M., Ardanuy C., et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998, 42(1):53-58.
47. Tängdén T., Eriksson B.M., Melhus A., Svennblad B., Cars O. Radical reduction of cephalosporin use at a tertiary hospital after educational antibiotic intervention during an outbreak of extended-spectrum {beta}-lactamase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2011, 66:1161-1167.
48. Rahal J.J., Urban C., Segal-Maurer S. Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis 2002, 34(4):499-503.
49. Kirkland K.B. Taking off the gloves: toward a less dogmatic approach to the use of contact isolation. Clin Infect Dis 2009, 48(6):766-771.
50. Société française d'hygiène hospitalière. Recommandations pour l'hygiène des mains. Available at: Accessed 2011. http://sfhh.net/telechargement/recommandations_hygienemain2009.pdf.
51. Société française d'hygiène hospitalière. Prévention de la transmission croisée: précautions complémentaires contact. Available at: Accessed 2011. http://sfhh.net/telechargement/recommandations_hygienemain2009.pdf.
52. Venier A.G., Zaro-Goni D., Pefau M., et al. Performance of hand hygiene in 214 healthcare facilities in South-Western France. J Hosp Infect 2009, 71(3):280-282. [Epub 2009].
53. Lucet J.C., Armand-Lefevre L., Laurichesse J.J., et al. Rapid control of an outbreak of vancomycin-resistant enterococci in a French university hospital. J Hosp Infect 2007, 67(1):42-48. [Epub 2007].
54. Haut Conseil de la santé publique. Rapport relatif à la maîtrise de l'émergence et de la diffusion des entérocoques résistants aux glycopeptides (ERG) dans les établissements de santé français. Available at: accessed.
55. Schwaber M.J., Lev B., Israeli A., Solter E., Smollan G., Rubinovitch B., et al. The Israel Carbapenem-Resistant Enterobacteriaceae Working Group. Containment of a Country-wide outbreak of Carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011, 52:848-855.
56. Ostrowsky B.E., Venkataraman L., D'Agata E.M., Gold H.S., DeGirolami P.C., Samore M.H. Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. Arch Intern Med 1999, 159(13):1467-1472.
57. Jarlier V., Trystram D., Brun-Buisson C., et al. Curbing methicillin-resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch Intern Med 2010, 170(6):552-559.
58. Apisarnthanarak A., Pinitchai U., Thongphubeth K., Yuekyen C., Warren D.K., Fraser V.J. A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in three intensive care units in a Thai tertiary care center: a 3-year study. Clin Infect Dis 2008, 47(6):760-767.
59. Gauzit R., Gutmann L., Brun-Buisson C., Jarlier V., Fantin B. Recommandations de bon usage des carbapénèmes. Antibiotiques 2010, 12:183-189.
60. Lucet J.C., Andremont A., Coignard B. Les entérocoques résistants aux glycopeptides (ERG): situation épidémiologique, mesures de contrôle actuelles et enjeux à venir. Bull Epidemiol Hebdo 2008, 386-390. http://www.invs.sante.fr/beh/2008/41_42/beh_41_42_2008.pdf ed.